Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (1): 1-10.doi: 10.3760/cma.j.cn371439-20201208-00001
Received:2020-12-08
Revised:2020-12-13
Online:2021-01-08
Published:2021-01-21
"
| 观测指标 | 评分 | ||
|---|---|---|---|
| 1 | 2 | 3 | |
| 肝性脑病(期别) | 0 | 1~2 | 3~4 |
| 腹腔积液 | 无 | 少量 | 中等量 |
| 白蛋白(g/L) | >35 | 28~35 | <28 |
| 凝血酶原时间延长(秒) | <4 | 4~6 | >6 |
| 总胆红素(μmol/L) | <34 | 34~50 | >50 |
"
| 分期 | T | N | M |
|---|---|---|---|
| ⅠA | T1a | N0 | M0 |
| ⅠB | T1b | N0 | M0 |
| Ⅱ | T2 | N0 | M0 |
| ⅢA | T3 | N0 | M0 |
| ⅢB | T4 | N0 | M0 |
| ⅣA | 任何T | N1 | M0 |
| ⅣB | 任何T | 任何N | M1 |
| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
pmid: 26808342 |
| [2] |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019,394(10204):1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
doi: 10.1016/S0140-6736(19)30427-1 pmid: 31248666 |
| [3] | 欧美同学会医师协会肝胆分会, 中国研究型医院学会分子诊断专委会, 中国临床肿瘤学会肝癌专委会, 等. 肝胆肿瘤分子诊断临床应用专家共识[J]. 中华肝胆外科杂志, 2020,26(2):81-89. DOI: 10.3760/cma.j.issn.1007-8118.2020.02.001. |
| [4] | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020,40(2):121-138. DOI: 10.19538/j.cjps.issn1005-2208.2020.02.01. |
| [5] |
Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging—a systematic review and meta-analysis[J]. Radiology, 2015,275(1):97-109. DOI: 10.1148/radiol.14140690.
pmid: 25559230 |
| [6] |
Liu X, Jiang H, Chen J, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis[J]. Liver Transpl, 2017,23(12):1505-1518. DOI: 10.1002/lt.24867.
pmid: 28886231 |
| [7] |
Rao SX, Wang J, Wang J, et al. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: gadoxetic acid disodium[J]. J Dig Dis, 2019,20(2):54-61. DOI: 10.1111/1751-2980.12707.
pmid: 30693659 |
| [8] |
Zeng MS, Ye HY, Guo L, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: a multicenter, open-label, phase Ⅲ study[J]. Hepatobiliary Pancreat Dis Int, 2013,12(6):607-616. DOI: 10.1016/s1499-3872(13)60096-x.
doi: 10.1016/s1499-3872(13)60096-x pmid: 24322746 |
| [9] |
Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase Ⅲ, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease[J]. Invest Radiol, 2010,45(3):133-141. DOI: 10.1097/RLI.0b013e3181caea5b.
pmid: 20098330 |
| [10] |
Yoo SH, Choi JY, Jang JW, et al. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma[J]. Ann Surg Oncol, 2013,20(9):2893-2900. DOI: 10.1245/s10434-013-3001-y.
pmid: 23649931 |
| [11] |
Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology, 2008,47(1):97-104. DOI: 10.1002/hep.21966.
doi: 10.1002/hep.21966 pmid: 18069697 |
| [12] | 中国临床肿瘤学会. 原发性肝癌诊疗指南[M]. 北京: 人民卫生出版社, 2020. |
| [13] |
Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT[J]. J Hepatol, 2014,61(1):82-88. DOI: 10.1016/j.jhep.2014.03.012.
doi: 10.1016/j.jhep.2014.04.005 |
| [14] |
Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group[J]. Ann Surg, 2013,257(5):929-937. DOI: 10.1097/SLA.0b013e31828329b8.
doi: 10.1097/SLA.0b013e31828329b8 pmid: 23426336 |
| [15] |
Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma[J]. Semin Radiat Oncol, 2017,27(3):247-255. DOI: 10.1016/j.semradonc.2017.02.002.
doi: 10.1016/j.semradonc.2017.02.002 pmid: 28577832 |
| [16] |
Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006,243(3):321-328. DOI: 10.1097/01.sla.0000201480.65519.b8.
doi: 10.1097/01.sla.0000201480.65519.b8 pmid: 16495695 |
| [17] |
Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol, 2012,57(4):794-802. DOI: 10.1016/j.jhep.2012.05.007.
doi: 10.1016/j.jhep.2012.05.007 pmid: 22634125 |
| [18] |
Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma[J]. Br J Surg, 2017,104(13):1775-1784. DOI: 10.1002/bjs.10677.
doi: 10.1002/bjs.10677 pmid: 29091283 |
| [19] |
Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial[J]. J Clin Oncol, 2013,31(4):426-432. DOI: 10.1200/JCO.2012.42.9936.
pmid: 23269991 |
| [20] |
Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]. Cancer, 2010,116(23):5452-5460. DOI: 10.1002/cncr.25314.
doi: 10.1002/cncr.25314 pmid: 20672352 |
| [21] |
Chen QW, Ying HF, Gao S, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2016,40(3):309-314. DOI: 10.1016/j.clinre.2015.07.008.
doi: 10.1016/j.clinre.2015.07.008 pmid: 26428660 |
| [22] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390. DOI: 10.1056/NEJMoa0708857.
doi: 10.1056/NEJMoa0708857 pmid: 18650514 |
| [23] |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of so-rafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009,10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7.
pmid: 19095497 |
| [24] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
doi: 10.1016/S0140-6736(18)30207-1 pmid: 29433850 |
| [25] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020,382(20):1894-1905. DOI: 10.1016/S0140-6736(18)30207-1.
doi: 10.1056/NEJMoa1915745 pmid: 32402160 |
| [26] |
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013,31(28):3501-3508. DOI: 10.1200/JCO.2012.44.5643.
doi: 10.1200/JCO.2012.44.5643 pmid: 23980077 |
| [27] |
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9.
doi: 10.1016/S0140-6736(16)32453-9 pmid: 27932229 |
| [28] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
doi: 10.1016/S0140-6736(17)31046-2 pmid: 28434648 |
| [29] |
Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018,19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6.
doi: 10.1016/S1470-2045(18)30351-6 pmid: 29875066 |
| [30] |
Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with pre-viously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020,21(4):571-580. DOI: 10.1016/S1470-2045(20)30011-5.
doi: 10.1016/S1470-2045(20)30011-5 pmid: 32112738 |
| [31] |
Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis[J]. Am J Roentgenol Radium Ther Nucl Med, 1965,93:200-208.
pmid: 14243011 |
| [32] |
Durand-Labrunie J, Baumann AS, Ayav A, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2020,107(1):116-125. DOI: 10.1016/j.ijrobp.2019.12.004.
doi: 10.1016/j.ijrobp.2019.12.004 pmid: 32001057 |
| [33] |
Takeda A, Sanuki N, Tsurugai Y, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation[J]. Cancer, 2016,122(13):2041-2049. DOI: 10.1002/cncr.30008.
doi: 10.1002/cncr.30008 pmid: 27062278 |
| [34] |
Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of ste-reotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies[J]. Radiother Oncol, 2019,131:135-144. DOI: 10.1016/j.radonc.2018.12.005.
doi: 10.1016/j.radonc.2018.12.005 pmid: 30773180 |
| [35] |
Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients[J]. Acta Oncol, 2014,53(3):399-404. DOI: 10.3109/0284186X.2013.820342.
doi: 10.3109/0284186X.2013.820342 pmid: 23962244 |
| [36] |
Su TS, Liang P, Liang J, et al. Long-term survival analysis of ste-reotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2017,98(3):639-646. DOI: 10.1016/j.ijrobp.2017.02.095.
doi: 10.1016/j.ijrobp.2017.02.095 pmid: 28581406 |
| [37] |
Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis[J]. Hepatology, 2019,69(6):2533-2545. DOI: 10.1002/hep.30591.
doi: 10.1002/hep.30591 pmid: 30805950 |
| [38] |
Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma[J]. J Hepatol, 2020,73(1):121-129. DOI: 10.1016/j.jhep.2020.03.005.
doi: 10.1016/j.jhep.2020.03.005 pmid: 32165253 |
| [39] |
Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma[J]. Liver Int, 2005,25(6):1189-1196. DOI: 10.1111/j.1478-3231.2005.01170.x.
doi: 10.1111/j.1478-3231.2005.01170.x pmid: 16343071 |
| [40] |
Kim KH, Kim MS, Chang JS, et al. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma[J]. Liver Int, 2014,34(5):784-794. DOI: 10.1111/liv.12436.
doi: 10.1111/liv.12436 |
| [41] |
Koom WS, Seong J, Han KH, et al. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas?[J]. Int J Radiat Oncol Biol Phys, 2010,77(5):1433-1440. DOI: 10.1016/j.ijrobp.2009.07.1676.
doi: 10.1016/j.ijrobp.2009.07.1676 pmid: 19896779 |
| [42] |
Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis[J]. JAMA Oncol, 2015,1(6):756-765. DOI: 10.1001/jamaoncol.2015.2189.
doi: 10.1001/jamaoncol.2015.2189 pmid: 26182200 |
| [43] |
Chan SL, Chong CC, Chan AW, et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016[J]. World J Gastroenterol, 2016,22(32):7289-7300. DOI: 10.3748/wjg.v22.i32.7289.
doi: 10.3748/wjg.v22.i32.7289 pmid: 27621575 |
| [44] |
Im JH, Yoon SM, Park HC, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area[J]. Liver Int, 2017,37(1):90-100. DOI: 10.1111/liv.13191.
doi: 10.1111/liv.13191 pmid: 27317941 |
| [45] |
Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012,82(5):2004-2011. DOI: 10.1016/j.ijrobp.2011.03.019.
doi: 10.1016/j.ijrobp.2011.03.019 pmid: 21621346 |
| [46] |
Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018,4(5):661-669. DOI: 10.1001/jamaoncol.2017.5847.
doi: 10.1001/jamaoncol.2017.5847 pmid: 29543938 |
| [47] |
Kim YJ, Jung J, Joo JH, et al. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona Clinic Liver Cancer stage C[J]. Radiother Oncol, 2019,141:95-100. DOI: 10.1016/j.radonc.2019.08.009.
doi: 10.1016/j.radonc.2019.08.009 pmid: 31506181 |
| [48] |
Lee IJ, Chung JW, Kim HC, et al. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors[J]. J Vasc Interv Radiol, 2009,20(1):22-29. DOI: 10.1016/j.jvir.2008.09.030.
doi: 10.1016/j.jvir.2008.09.030 |
| [49] |
Rim CH, Kim CY, Yang DS, et al. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: a meta-analysis and systemic review[J]. Radiother Oncol, 2018,129(1):123-129. DOI: 10.1016/j.radonc.2018.02.030.
doi: 10.1016/j.radonc.2018.02.030 pmid: 29606524 |
| [50] |
Katz AW, Chawla S, Qu Z, et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation[J]. Int J Radiat Oncol Biol Phys, 2012,83(3):895-900. DOI: 10.1016/j.ijrobp.2011.08.032.
doi: 10.1016/j.ijrobp.2011.08.032 pmid: 22172906 |
| [51] |
O'Connor JK, Trotter J, Davis GL, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J]. Liver Transpl, 2012,18(8):949-954. DOI: 10.1002/lt.23439.
doi: 10.1002/lt.23439 pmid: 22467602 |
| [52] |
Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J Hepatol, 2017,67(1):92-99. DOI: 10.1016/j.jhep.2017.02.022.
doi: 10.1016/j.jhep.2017.02.022 pmid: 28257902 |
| [53] |
Chang CM, Wei CK, Lee CH, et al. Long-term follow-up of central hepatocellular carcinoma in comparison with non-central hepatocellular carcinoma[J]. Hepatogastroenterology, 2012,59(114):492-495. DOI: 10.5754/hge11361.
doi: 10.5754/hge11361 pmid: 21940385 |
| [54] |
Wang WH, Wang Z, Wu JX, et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels[J]. Liver Int, 2015,35(12):2603-2610. DOI: 10.1111/liv.12857.
doi: 10.1111/liv.12857 pmid: 25939444 |
| [55] |
Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019,37(24):2141-2151. DOI: 10.1200/JCO.18.02184.
doi: 10.1200/JCO.18.02184 pmid: 31283409 |
| [56] |
Park YJ, Lim DH, Paik SW, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma[J]. J Gastroenterol, 2006,41(11):1099-1106. DOI: 10.1007/s00535-006-1895-x.
doi: 10.1007/s00535-006-1895-x |
| [57] |
Zhou LY, Zeng ZC, Fan J, et al. Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors[J]. BMC Cancer, 2014,14:878. DOI: 10.1186/1471-2407-14-878.
doi: 10.1186/1471-2407-14-878 pmid: 25421498 |
| [58] |
He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy[J]. Cancer, 2009,115(12):2710-2720. DOI: 10.1002/cncr.24300.
doi: 10.1002/cncr.24300 pmid: 19382203 |
| [59] |
Jiang W, Zeng ZC, Zhang JY, et al. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma[J]. Clin Exp Metastasis, 2012,29(3):197-205. DOI: 10.1007/s10585-011-9442-4.
doi: 10.1007/s10585-011-9442-4 pmid: 22173728 |
| [60] |
Park Y, Kim KS, Kim K, et al. Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study[J]. J Neurooncol, 2015,125(2):377-383. DOI: 10.1007/s11060-015-1926-7.
doi: 10.1007/s11060-015-1926-7 pmid: 26342711 |
| [61] |
Wang MH, Ji Y, Zeng ZC, et al. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume[J]. Int J Radiat Oncol Biol Phys, 2010,76(2):467-476. DOI: 10.1016/j.ijrobp.2009.01.057.
doi: 10.1016/j.ijrobp.2009.01.057 pmid: 19406586 |
| [62] |
Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma[J]. Radiother Oncol, 2014,111(3):412-417. DOI: 10.1016/j.radonc.2014.05.002.
doi: 10.1016/j.radonc.2014.05.002 |
| [63] |
Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication[J]. Int J Radiat Oncol Biol Phys, 2010,78(4):1073-1080. DOI: 10.1016/j.ijrobp.2009.09.009.
doi: 10.1016/j.ijrobp.2009.09.009 pmid: 20207492 |
| [64] |
Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010,76(3 Suppl):S94-S100. DOI: 10.1016/j.ijrobp.2009.06.092.
doi: 10.1016/j.ijrobp.2009.06.092 pmid: 20171524 |
| [65] |
Koay EJ, Owen D, Das P. Radiation-induced liver disease and mo-dern radiotherapy[J]. Semin Radiat Oncol, 2018,28(4):321-331. DOI: 10.1016/j.semradonc.2018.06.007.
doi: 10.1016/j.semradonc.2018.06.007 pmid: 30309642 |
| [66] |
Hu Y, Zhou YK, Chen YX, et al. 4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy[J]. Med Phys, 2016,43(7):4335. DOI: 10.1118/1.4953190.
doi: 10.1118/1.4953190 pmid: 27370148 |
| [67] |
中华学会放射肿瘤学分会. 2016年原发性肝癌放疗共识[J]. 中华放射肿瘤学杂志, 2016,25(11):1141-1150. DOI: 10.3760/cma.j.issn.1004-4221.2016.11.001.
doi: 10.3760/cma.j.issn.1004-4221.2016.11.001 |
| [68] | 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华临床感染病杂志, 2019,12(6):401-428. DOI: 10.3760/cma.j.issn.1674-2397.2019.06.001. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
